The Drug Enforcement Administration classified the drug methylenedioxymethamphetamine, MDMA, also known as Ecstacy, as a Schedule I controlled substance on July 1, 1985. The controversy surrounding the classification of MDMA is related to the question of its efficacy as an adjunct to psychotherapy and the larger issue of how to regulate the production and use of designer drugs. The authors review the literature on MDMA and its predecessor, MDA, a substance that differs from MDMA by one methyl group.
A retrospective study of forty-one consecutively admitted adolescent psychiatric patients who were not referred for substance abuse problems revealed a 71 percent rate of diagnosable abuse. Clinical interview, drug screening, and family history were assessed for their relative contribution to diagnoses. A conduct disorder diagnosis was found to be highly correlated with substance abuse. Both clinical interview and drug screening were found to be useful in diagnosing covert substance abuse. Covert drug abuse is a problem which can be uncovered by a clinical evaluation approach, including systematic clinical interviews and urine drug screening.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.